"The clinical implication of the current study is that treatment decisions must account for the possibility of neutralizing antibody formation."

-- Richard A. Rudick, et al. Incidence and significance of neutralizing antibodies to interferon-beta-1a in multiple sclerosis, Neurology 1998; 50, p.1271.

Welcome to a discussion on the incidence and biological significance of neutralizing antibodies to interferon b-1a, from the Avonex^® trial.

If you did not receive the first NeuroCAST email two weeks ago, we recommend that you view Session I prior to reviewing Session II.

Begin Session II
Next